Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$0.00
EPS est.
$-0.01
EPS surprise
+100.00%
1-day move
+2.17%
Caris Life Sciences reported an EPS of $0.00, which is a 100% surprise compared to expectations, although no revenue figures were provided. The stock reacted positively, increasing by 2.17%. Investors may be encouraged by the EPS surprise, but the lack of revenue data and management commentary leaves uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.00 | N/A | +100.00% |
| Revenue | — | N/A | — |
No transcript is on record for this earnings call, so the analysis is based solely on numerical results.
Caris Life Sciences, Inc. is a biotechnology company focused on precision medicine and molecular profiling. Operating in the health care sector, it aims to improve patient outcomes through advanced diagnostics and personalized treatment options.
Last quarter
In the last quarter, Caris Life Sciences reported an earnings surprise of 100%, with EPS at $0.00 compared to an estimate of -$0.02. The stock reacted positively, gaining 3.71% the following day.
EPS beat streak
4Q
EPS beat rate
88%
Avg EPS surprise
+547.12%
Avg 1-day reaction
+1.51%
Overall expectations are mixed as analysts await clarity on revenue growth and profitability. The company has a history of beating EPS estimates, which could influence market sentiment.
Bull case
If Caris continues its trend of beating EPS estimates, it could signal strong operational performance and growth potential, leading to increased investor confidence.
Bear case
Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a significant drop in stock price, as investors may reassess its valuation.
The print will turn on these.
Q1
What is the expected EPS for this quarter?
Given the company's recent history of beating EPS estimates, this number will be crucial for investor sentiment.
Q2
How is revenue growth tracking compared to previous quarters?
Investors will be keen to understand if the company can maintain its growth trajectory, which is vital for long-term success.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may be underestimating the potential for Caris to exceed EPS expectations due to its recent operational improvements.
Supporting evidence
The company has a 100% EPS beat rate in the last four quarters, indicating strong execution.
Options pricing suggests a significant move, which may reflect heightened investor interest and confidence.
Recent stock performance has shown resilience even in challenging market conditions.
Key risk
If the EPS comes in below $0.00, it could undermine the positive sentiment surrounding the stock.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around the company's ability to sustain growth and profitability amidst a competitive landscape.
Bull confirmed if
An EPS of $0.05 or higher would confirm strong operational performance.
Bear confirmed if
An EPS below $0.00 could indicate potential issues with profitability.
What the market is pricing for the move.
Implied Move
±7.61%
Historical Avg
±4.9%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±7.6% while CAI has averaged ±4.9% over the last 5 prints — setup is pricing rich.
ATM IV
0.9%
30d HV
90.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Caris beats expectations, history suggests the stock could rise by around 0.82%, confirming strong operational performance.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a decline of around 5.64%, as investors reassess the company's growth prospects.
The lines on the call that would change the story.